Arbiter Partners Capital Management RNA trades
Paul Isaac
Paul Isaac Atrium Therapeutics, Inc stake
total: 302
Trades details
- Total transactions:
- 3
- New positions:
- 1
- Added:
- 1
- Reduced:
- 1
- Held since:
- 2026 Q1
- Held for:
- 3 quarters
- Latest activity:
- 2026 Q3
According to 2026 Q3 report, Paul Isaac holds 311,719 Atrium Therapeutics, Inc (RNA) shares with a market value of roughly $2.58M accounting for 1.14% of the overall portfolio. To date, the estimated cost basis is nearly $13.42 for "buy" trades and estimated average "sell" price is $8.28. Arbiter Partners Capital Management first purchased RNA in 2026 Q1, initially acquiring 230,000 shares. Since the initial investment in Atrium Therapeutics, Inc (RNA), Arbiter Partners Capital Management has made 2 more transactions.
When did Paul Isaac buy Atrium Therapeutics, Inc (RNA)?
Paul Isaac first invested in Atrium Therapeutics, Inc (RNA) in 2026 Q1 at the reported quarter-end price of $13.37 per share.
What's the cost basis of Arbiter Partners Capital Management's RNA stake?
The estimated cost basis for Atrium Therapeutics, Inc (RNA) stake is around $13.42 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $13.42
- Weighted AVG sell price:
- $8.28
Paul Isaac's historical trades in Atrium Therapeutics, Inc
3 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q3
|
1.14%
|
311,719
|
$8.28
|
$2,581,033
|
-40.35% (-210,857)
|
-0.48%
|
|
2026 Q2
|
1.91%
|
522,576
|
$13.45
|
$7,028,648
|
+127.21% (+292,576)
|
+1.07%
|
|
2026 Q1
|
2.09%
|
230,000
|
$13.37
|
$3,075,100
|
new
|
+2.09%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.